Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOLVER: Dolutegravir/Lamivudine in Virologically Suppressed HIV-1 Subjects With Prior Lamivudine Resistance
NCT04880785Phase 2Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Jul 2021
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of dolutegravir, lamivudine in human immunodeficiency virus infection (HIV), sponsored by Fundación SEIMC-GeSIDA. Started Jul 2021; status: completed.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04880785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880785.